Efficacy of topical cysteamine in nephropathic cystinosis

被引:12
|
作者
Al-Hemidan, Amal [1 ]
Shoughy, Samir S. [2 ,3 ]
Kozak, Igor [4 ]
Tabbara, Khalid F. [2 ,3 ,5 ,6 ]
机构
[1] Habib Med Grp, Ophthalmol Dept, Riyadh, Saudi Arabia
[2] Eye Ctr, Dept Ophthalmol, Riyadh, Saudi Arabia
[3] Eye Fdn Res Ophthalmol, Riyadh, Saudi Arabia
[4] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia
[5] King Saud Univ, Dept Ophthalmol, Coll Med, Riyadh, Saudi Arabia
[6] Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA
关键词
CORNEAL CRYSTALS; CLINICAL-TRIAL; MANIFESTATIONS; THERAPY; DISEASE;
D O I
10.1136/bjophthalmol-2016-309278
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose The aim of this study is to evaluate the efficacy of topical cysteamine 0.55% eye drops in the treatment of corneal cystine crystal deposits in patients with nephropathic cystinosis. Methods Thirty-two patients with nephropathic cystinosis were prospectively included in the study. Patients with corneal cystinosis were treated with topical cysteamine 0.55% eye drops. They were examined before treatment, on each monthly visit and after treatment at the last follow-up. Photophobia was classified as grade 0 (none) for no photophobia, grade 1 (mild) for photophobia in bright light, grade 2 (moderate) for photophobia in room light and grade 3 (severe) for photophobia in dim light. Corneal cystine crystals were graded as grade 0=none, grade 1=1-10 crystals/mm(2), grade 2=11-50 crystals/mm(2), grade 3=more than 50 crystals/mm(2). The main outcome measure was evaluation of photophobia and resolution of corneal cystine crystals. Results There were 13 male and 19 female patients. The mean age was 8 years with an age range of 8 months to 19 years. The mean follow-up period was 4.1 years with a range of 2-8 years. Improvement of photophobia was not clinically significant in symptomatic patients. Patients displayed statistically significant worsening of corneal cystine deposits during the follow-up period. Conclusions This study has shown that topical 0.55% cysteamine eye drops may have limited effects in decreasing the corneal cystine deposits in patients with severe forms of nephropathic cystinosis.
引用
收藏
页码:1234 / 1237
页数:4
相关论文
共 50 条
  • [31] NEPHROPATHIC CYSTINOSIS - EFFECT OF LONG-TERM CYSTEAMINE THERAPY
    PROESMANS, W
    BATEN, E
    HOOGMARTENS, J
    BRUYNEEL, P
    [J]. CLINICAL NEPHROLOGY, 1987, 27 (06) : 309 - 312
  • [32] EARLY CYSTEAMINE TREATMENT FOR OF NEPHROPATHIC CYSTINOSIS: RENAL OUTCOME OF RUSSIAN CHILDREN
    Maltseva, Valentina
    Ananin, Petr
    Vashurina, Tatyana
    Savostyanov, Kirill
    Pushkov, Alexander
    Zrobok, Olga
    Fisenko, Andrey
    Tsygin, Alexey
    [J]. PEDIATRIC NEPHROLOGY, 2022, 37 (11) : 2923 - 2924
  • [33] Nephropathic cystinosis in adults: Natural history and effects of oral cysteamine therapy
    Gahl, William A.
    Balog, Joan Z.
    Kleta, Robert
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 147 (04) : 242 - 250
  • [34] Intravenous cysteamine in the treatment of nephropathic cystinosis: Association with elevated transaminase levels
    Bendel-Stenzel, MR
    Kim, YK
    [J]. PEDIATRIC RESEARCH, 2002, 51 (04) : 436A - 436A
  • [35] Corneal crystals in nephropathic cystinosis: Natural history and treatment with cysteamine eyedrops
    Gahl, WA
    Kuehl, EM
    Iwata, F
    Lindblad, A
    Kaiser-Kupfer, MI
    [J]. MOLECULAR GENETICS AND METABOLISM, 2000, 71 (1-2) : 100 - 120
  • [36] CYSTEAMINE EYE DROPS FOR TREATMENT OF CORNEAL CYSTINE DEPOSITS IN NEPHROPATHIC CYSTINOSIS
    GRAF, M
    GROTE, A
    WAGNER, F
    [J]. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 1992, 201 (01) : 48 - 50
  • [37] Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults
    Brodin-Sartorius, Albane
    Tete, Marie-Josephe
    Niaudet, Patrick
    Antignac, Corinne
    Guest, Genevieve
    Ottolenghi, Chris
    Charbit, Marina
    Moyse, Dominique
    Legendre, Christophe
    Lesavre, Philippe
    Cochat, Pierre
    Servais, Aude
    [J]. KIDNEY INTERNATIONAL, 2012, 81 (02) : 179 - 189
  • [38] Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis
    Kaur, Sukhmandeep
    Sarma, Phulen
    Kaur, Hardeep
    Prajapat, Manisha
    Shekhar, Nishant
    Bhattacharyya, Jaimini
    Kaur, Harpinder
    Kumar, Subodh
    Medhi, Bikash
    Ram, Jagat
    Das, Dipankar
    Avti, Pramod
    Prakash, Ajay
    Singh, Rahul
    Bhattacharyya, Anusuya
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2021, 223 : 275 - 285
  • [39] EFFECTS OF EARLY CYSTEAMINE THERAPY ON THYROID-FUNCTION AND GROWTH IN NEPHROPATHIC CYSTINOSIS
    KIMONIS, VE
    TROENDLE, J
    ROSE, SR
    YANG, ML
    MARKELLO, TC
    GAHL, WA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (11): : 3257 - 3261
  • [40] A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
    van Stein, Christina
    Klank, Sabrina
    Grueneberg, Marianne
    Ottolenghi, Chris
    Grebe, Jurgen
    Reunert, Janine
    Harms, Erik
    Marquardt, Thorsten
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)